Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 30Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13durvalumab 12Ipilimumab 12Capecitabine 12Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Busulfan × Clear all
NCT00822393 2020-07-30

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

medac GmbH

Phase 3 Completed
570 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡